請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25500
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺 | |
dc.contributor.author | Sheng-Ju Hsu | en |
dc.contributor.author | 徐聖如 | zh_TW |
dc.date.accessioned | 2021-06-08T06:16:04Z | - |
dc.date.copyright | 2007-02-02 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-01-30 | |
dc.identifier.citation | 1. Information received from the Internet Homepages of the Department of Health, Taiwan, R. O. C. http://www.doh.gov.tw, Internet Communication 2007.
2. Baylin, S. B.; Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 2006, 6 (2), 107-116. 3. Lund, A. H.; van, L. M. Epigenetics and cancer. Genes Dev. 2004, 18 (19), 2315-2335. 4. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5 (9), 769-784. 5. De Ruijter, A. J. M.; Van Gennip, A. H.; Caron, H. N.; Kemp, S.; Van Kuilenburg, A. B. P. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal 2003, 370, 737-749. 6. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 2001, 8 (12), 1505-1511. 7. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1 (4), 287-299. 8. Rosato, R. R.; Grant, S. Histone deacetylase inhibitors in clinical development. Expert Opinion on Investigational Drugs 2004, 13 (1), 21-38. 9. Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92 (15), 1210-1216. 10. Marks, P. A.; Miller, T.; Richon, V. M. Histone deacetylases. Current Opinion in Pharmacology 2003, 3 (4), 344-351. 11. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. Journal of Medicinal Chemistry 2003, 46 (24), 5097-5116. 12. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9 (1), 3-16. 13. Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 angstrom resolution. Nature 1997, 389 (6648), 251-260. 14. Norton, V. G.; Imai, B. S.; Yau, P.; Bradbury, E. M. Histone Acetylation Reduces Nucleosome Core Particle Linking Number Change. Cell 1989, 57 (3), 449-457. 15. Jenuwein, T. Re-SET-ting heterochromatin by histone methyltransferases. Trends in Cell Biology 2001, 11 (6), 266-273. 16. Drummond, D. C.; Noble, C. O.; Kirpotin, D. B.; Guo, Z. X.; Scott, G. K.; Benz, C. C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology 2005, 45, 495-528. 17. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25 (3), 261-309. 18. Van, L. C.; Emiliani, S.; Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996, 5 (4-5), 245-253. 19. Glaser, K. B.; Staver, M. J.; Waring, J. F.; Stender, J.; Ulrich, R. G.; Davidsen, S. K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2 (2), 151-163. 20. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics - An epicenter of gene regulation: Histones and histone-modifying enzymes. Angewandte Chemie-International Edition 2005, 44 (21), 3186-3216. 21. Sterner, D. E.; Berger, S. L. Acetylation of histones and transcription-related factors. Microbiology and Molecular Biology Reviews 2000, 64 (2), 435-+. 22. Lachner, M.; Jenuwein, T. The many faces of histone lysine methylation. Current Opinion in Cell Biology 2002, 14 (3), 286-298. 23. Cheung, W. L.; Ajiro, K.; Samejima, K.; Kloc, M.; Cheung, P.; Mizzen, C. A.; Beeser, A.; Etkin, L. D.; Chernoff, J.; Earnshaw, W. C.; Allis, C. D. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 2003, 113 (4), 507-517. 24. Jason, L. J.; Moore, S. C.; Lewis, J. D.; Lindsey, G.; Ausio, J. Histone ubiquitination: a tagging tail unfolds? Bioessays 2002, 24 (2), 166-174. 25. Nathan, D.; Sterner, D. E.; Berger, S. L. Histone modifications: Now summoning sumoylation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100 (23), 13118-13120. 26. Geiman, T. M.; Robertson, K. D. Chromatin remodeling, histone modifications, and DNA methylation - How does it all fit together? Journal of Cellular Biochemistry 2002, 87 (2), 117-125. 27. Claus, R.; Lubbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003, 22 (42), 6489-6496. 28. Nephew, K. P.; Huang, T. H. M. Epigenetic gene silencing in cancer initiation and progression. Cancer Letters 2003, 190 (2), 125-133. 29. Daujat, S.; Bauer, U. M.; Shah, V.; Turner, B.; Berger, S.; Kouzarides, T. Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr. Biol. 2002, 12 (24), 2090-2097. 30. Agalioti, T.; Chen, G.; Thanos, D. Deciphering the transcriptional histone acetylation code for a human gene. Cell 2002, 111 (3), 381-392. 31. Jacobs, S. A.; Taverna, S. D.; Zhang, Y.; Briggs, S. D.; Li, J.; Eissenberg, J. C.; Allis, C. D.; Khorasanizadeh, S. Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. EMBO J. 2001, 20 (18), 5232-5241. 32. Hassan, A. H.; Prochasson, P.; Neely, K. E.; Galasinski, S. C.; Chandy, M.; Carrozza, M. J.; Workman, J. L. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell 2002, 111 (3), 369-379. 33. Santos-Rosa, H.; Schneider, R.; Bannister, A. J.; Sherriff, J.; Bernstein, B. E.; Emre, N. C.; Schreiber, S. L.; Mellor, J.; Kouzarides, T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419 (6905), 407-411. 34. Zhang, X.; Yang, Z.; Khan, S. I.; Horton, J. R.; Tamaru, H.; Selker, E. U.; Cheng, X. Structural basis for the product specificity of histone lysine methyltransferases. Mol. Cell 2003, 12 (1), 177-185. 35. Juan, L. J.; Shia, W. J.; Chen, M. H.; Yang, W. M.; Seto, E.; Lin, Y. S.; Wu, C. W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 2000, 275 (27), 20436-20443. 36. Fu, M.; Rao, M.; Wang, C.; Sakamaki, T.; Wang, J.; Di, V. D.; Zhang, X.; Albanese, C.; Balk, S.; Chang, C.; Fan, S.; Rosen, E.; Palvimo, J. J.; Janne, O. A.; Muratoglu, S.; Avantaggiati, M. L.; Pestell, R. G. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol. Cell Biol. 2003, 23 (23), 8563-8575. 37. Wang, C.; Fu, M.; Angeletti, R. H.; Siconolfi-Baez, L.; Reutens, A. T.; Albanese, C.; Lisanti, M. P.; Katzenellenbogen, B. S.; Kato, S.; Hopp, T.; Fuqua, S. A.; Lopez, G. N.; Kushner, P. J.; Pestell, R. G. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 2001, 276 (21), 18375-18383. 38. Herrera, J. E.; Sakaguchi, K.; Bergel, M.; Trieschmann, L.; Nakatani, Y.; Bustin, M. Specific acetylation of chromosomal protein HMG-17 by PCAF alters its interaction with nucleosomes. Mol. Cell Biol. 1999, 19 (5), 3466-3473. 39. Lin, H. Y.; Chen, C. S.; Lin, S. P.; Weng, J. R.; Chen, C. S. Targeting histone deacetylase in cancer therapy. Medicinal Research Reviews 2006, 26 (4), 397-413. 40. Kim, D. H.; Kim, M.; Kwon, H. J. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. Journal of Biochemistry and Molecular Biology 2003, 36 (1), 110-119. 41. Pandolfi, P. P. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol. 2001, 48 Suppl 1, S17-S19. 42. Lin, R. J.; Sternsdorf, T.; Tini, M.; Evans, R. M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001, 20 (49), 7204-7215. 43. Pasqualucci, L.; Bereschenko, O.; Niu, H. F.; Klein, U.; Basso, K.; Guglielmino, R.; Cattoretti, G.; la-Favera, R. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leukemia & Lymphoma 2003, 44, S5-S12. 44. Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R. Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003, 310 (2), 529-536. 45. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, C.; Minucci, S.; Pelicci, P. G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway (vol 11, pg 71, 2005). Nature Medicine 2005, 11 (2), 233. 46. Fraga, M. F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N. G.; Perez-Rosado, A.; Calvo, E.; Lopez, J. A.; Cano, A.; Calasanz, M. J.; Colomer, D.; Piris, M. A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37 (4), 391-400. 47. Monneret, C. Histone deacetylase inhibitors. European Journal of Medicinal Chemistry 2005, 40 (1), 1-13. 48. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer 2006, 6 (1), 38-51. 49. Gore, S. D.; Carducci, M. A. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs 2000, 9 (12), 2923-2934. 50. Breslow, R.; Belvedere, S.; Gershell, L. Development of cytodifferentiating agents for cancer chemotherapy. Helvetica Chimica Acta 2000, 83 (8), 1685-1692. 51. Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaka, Y.; Koizumi, K. New Antifungal Antibiotic, Trichostatin. Journal of Antibiotics 1976, 29 (1), 1-6. 52. Yoshida, M.; Nomura, S.; Beppu, T. Effects of Trichostatins on Differentiation of Murine Erythroleukemia-Cells. Cancer Research 1987, 47 (14), 3688-3691. 53. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and Specific-Inhibition of Mammalian Histone Deacetylase Both Invivo and Invitro by Trichostatin-A. Journal of Biological Chemistry 1990, 265 (28), 17174-17179. 54. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proceedings of the National Academy of Sciences of the United States of America 1996, 93 (12), 5705-5708. 55. Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America 1998, 95 (6), 3003-3007. 56. Remiszewski, S. W. The discovery of NVP-LAQ824: From concept to clinic. Current Medicinal Chemistry 2003, 10 (22), 2393-2402. 57. Remiszewski, S. W.; Sambucetti, L. C.; Bair, K. W.; Bontempo, J.; Cesarz, D.; Chandramouli, N.; Chen, R.; Cheung, M.; Cornell-Kennon, S.; Dean, K.; Diamantidis, G.; France, D.; Green, M. A.; Howell, K. L.; Kashi, R.; Kwon, P.; Lassota, P.; Martin, M. S.; Mou, Y.; Perez, L. B.; Sharma, S.; Smith, T.; Sorensen, E.; Taplin, F.; Trogani, N.; Versace, R.; Walker, H.; Weltchek-Engler, S.; Wood, A.; Wu, A.; Atadja, P. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]-phenyl]-2-propenamide (NVP-LAQ824). Journal of Medicinal Chemistry 2003, 46 (21), 4609-4624. 58. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. Journal of Medicinal Chemistry 1999, 42 (15), 3001-3003. 59. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proceedings of the National Academy of Sciences of the United States of America 1999, 96 (8), 4592-4597. 60. Elbeltagi, H. M.; Martens, A. C. M.; Lelieveld, P.; Haroun, E. A.; Hagenbeek, A. Acetyldinaline - A New Oral Cytostatic Drug with Impressive Differential Activity Against Leukemic-Cells and Normal Stem-Cells - Preclinical Studies in A Relevant Rat Model for Human Acute Myelocytic-Leukemia. Cancer Research 1993, 53 (13), 3008-3014. 61. Seelig, M. H.; Berger, M. R. Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. European Journal of Cancer 1996, 32A (11), 1968-1976. 62. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, An Antitumor Cyclic Tetrapeptide, Is An Irreversible Inhibitor of Mammalian Histone Deacetylase. Journal of Biological Chemistry 1993, 268 (30), 22429-22435. 63. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272 (5260), 408-411. 64. Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. Fr901228, A Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium-Violaceum No-968 .1. Taxonomy, Fermentation, Isolation, Physicochemical and Biological Properties, and Antitumor-Activity. Journal of Antibiotics 1994, 47 (3), 301-310. 65. Komatsu, Y.; Tomizaki, K.; Tsukamoto, M.; Kato, T.; Nishino, N. K.; Sato, S. G.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Research 2001, 61 (11), 4459-4466. 66. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proceedings of the National Academy of Sciences of the United States of America 2001, 98 (1), 87-92. 67. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100 (8), 4389-4394. 68. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401 (6749), 188-193. 69. Lu, Q.; Wang, D. S.; Chen, C. S.; Hu, Y. D.; Chen, C. S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. Journal of Medicinal Chemistry 2005, 48 (17), 5530-5535. 70. Gediya, L. K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.; Njar, V. C. O. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. Journal of Medicinal Chemistry 2005, 48 (15), 5047-5051. 71. Limpricht, H. The p-Toluyl-beta-propionic acid. Justus Liebigs Annalen der Chemie 1900, 312 (1/3), 110-117. 72. Ito, Y.; Kawatsuki, N.; Giri, B. P.; Yoshida, M.; Matsuura, T. Photochemistry of Meta-Substituted and Para-Substituted Aromatic Polycarbonyl Compounds. Journal of Organic Chemistry 1985, 50 (16), 2893-2904. 73. Matt, C.; Wagner, A.; Mioskowski, C. Novel transformation of primary nitroalkanes and primary alkyl bromides to the corresponding carboxylic acids. Journal of Organic Chemistry 1997, 62 (2), 234-235. 74. Bochis, R. J.; Chabala, J. C.; Harris, E.; Peterson, L. H.; Barash, L.; Beattie, T.; Brown, J. E.; Graham, D. W.; Waksmunski, F. S.; Tischler, M.; Joshua, H.; Smith, J.; Colwell, L. F.; Wyvratt, M. J.; Fisher, M. H.; Tamas, T.; Nicolich, S.; Schleim, K. D.; Wilks, G.; Olson, G. Benzylated 1,2,3-Triazoles As Anticoccidiostats. Journal of Medicinal Chemistry 1991, 34 (9), 2843-2852. 75. Thyes, M.; Lehmann, H. D.; Gries, J.; Konig, H.; Kretzschmar, R.; Kunze, J.; Lebkucher, R.; Lenke, D. 6-Aryl-4,5-Dihydro-3(2H)-Pyridazinones - A New Class of Compounds with Platelet-Aggregation Inhibiting and Hypotensive Activities. Journal of Medicinal Chemistry 1983, 26 (6), 800-807. 76. Curran, W. V.; Ross, A. 6-Phenyl-4,5-Dihydro-3(H-2)-Pyridazinones - Series of Hypotensive Agents. Journal of Medicinal Chemistry 1974, 17 (3), 273-281. 77. Chauhan, S. M. S.; Jain, N.; Kumar, A.; Srinivas, K. A. Copper(I) chloride catalyzed synthesis of diaryl ethers in ionic liquids under mild conditions. Synthetic Communications 2003, 33 (20), 3607-3614. 78. Hashimoto, N.; Aoyama, T.; Shioiri, T. New Methods and Reagents in Organic-Synthesis .14. A Simple Efficient Preparation of Methyl-Esters with Trimethylsilyldiazomethane (Tmschn2) and Its Application to Gas-Chromatographic Analysis of Fatty-Acids. Chemical & Pharmaceutical Bulletin 1981, 29 (5), 1475-1478. 79. Bumagin, N. A.; More, P. G.; Beletskaya, I. P. Synthesis of Substituted Cinnamic-Acids and Cinnamonitriles Via Palladium Catalyzed Coupling Reactions of Aryl Halides with Acrylic-Acid and Acrylonitrile in Aqueous-Media. Journal of Organometallic Chemistry 1989, 371 (3), 397-401. 80. Klemme, C. J.; Hunter, J. H. Synthesis of iodohippuric acids. I. 2,5-, 3,5-and 3,4-diiodohippuric acids. Journal of Organic Chemistry 1940, 5 (3), 227-234. 81. Lawson, E. C.; Kinney, W. A.; Luci, D. K.; Yabut, S. C.; Wisnoski, D.; Maryanoff, B. E. The Heck reaction with unprotected allylic amidines and guanidines. Tetrahedron Letters 2002, 43 (11), 1951-1953. 82. Tang, T. P.; Volkman, S. K.; Ellman, J. A. Asymmetric synthesis of protected 1,2-amino alcohols using tert-butanesulfinyl aldimines and ketimines. Journal of Organic Chemistry 2001, 66 (26), 8772-8778. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25500 | - |
dc.description.abstract | 本論文主旨為設計與合成suberoylanilide hydroxamic acid (SAHA)類似物作為潛能histone deacetylase (HDAC)抑制劑與抗癌劑。主要內容為將SAHA結構中與HDAC的金屬有結合作用的hydroxamic acid官能基固定住而設計出目標化合物,這些hydroxamic acid衍生物可分成兩類,一種是hydroxamic acid相連結於苯環上(1及2a,b),另一種則是建構於喹唑啉酮環中(3及4)。在化合物1的合成中,中間物5是從aniline經由六個反應步驟製備而成,其中包含Friedel-Crafts acylation(與succinic anhydride作用)產生linker接於苯環上,將羧酸化合物5進行酯化之後再與hydroxylamine作用可得到hydroxamic acid產物1。為合成化合物2a,b,含碘苯甲酸化合物25a,b經由Heck reaction與vinyl acetic acid反應之後,接著醯胺生成反應與水解反應可得到苯甲酸衍生物30a,b,之後再與methyl chloroformate反應,緊接著與O-benzylhydroxylamine作用,最後藉由氫化反應可得到hydroxmic acid 2a,b。含碘的喹唑啉酮化合物40及41是利用anthranilic acid經由三個反應步驟合成而得,接著進行Heck reaction與醯胺生成反應可分別產生44及45,而目前正準備將化合物44和45進行氫化反應以生成化合物3與4。目標化合物1、2a,b以及3的前驅化合物44藉由MTT分析方法對A549、AGS、HepG2、HT-29與PC-3五種人類癌細胞株進行體外細胞毒性測試。化合物2b顯示對A549、AGS、HepG2以及HT-29癌細胞株具有生長抑制活性,GI50在4.29-7.36 μM之間;化合物44也能抑制A549、AGS、HT-29 (最有效,GI50為1.54 μM)和PC-3癌細胞株活性。在酵素活性抑制分析方面,化合物2b被發現為一HDAC抑制劑(IC50=11.5 μM)。此外,化合物3與4的最後階段的合成工作未來可望能進行。 | zh_TW |
dc.description.abstract | The aim of this thesis is to design and synthesize homologues of suberoylanilide hydroxamic acid (SAHA) as potential histone deacetylase (HDAC) inhibitors and anticancer agents. Based on SAHA, the target compounds were designed by conformational restriction of the hydroxamic acid group involved in the metal binding interactions with HDAC. The designed hydroxamic acid derivatives are divided into two classes: with the hydroxamic acid group attached to a phenyl ring (1 and 2a,b) and built into a quinazolinone ring (3 and 4). In the synthesis of compound 1, the required intermediate 5 was prepared from aniline via six reaction steps, including a Friedel-Crafts acylation with succinic anhydride to attach the linker to the benzene ring. Esterification of acid 5 followed by treatment of hydroxylamine gave the hydroxamic acid product 1. To synthesize compounds 2a,b the benzoic acid derivatives 30a,b were prepared from iodo-substituted benzoates 25a,b via Heck reaction with vinylacetic acid and then amide formation and hydrolysis reactions. Treatment of acids 30a,b with methyl chloroformate followed by reaction with O-benzylhydroxylamine and hydrogenation led to hydroxamic acids 2a,b. The iodo-substituted quinazolinones 40 and 41, prepared from anthranilic acid via three reaction steps, were subjected to Heck reaction and then amide formation reaction to give 44 and 45, respectively. The hydrogenation reaction of compounds 44 and 45 will be carried out to produce the desired products 3 and 4, respectively. Target compounds 1 and 2a,b and the precursor compound 44 (for 3) were evaluated for the in vitro cytotoxic activity against five human cancer cell lines (A549, AGS, HepG2, HT-29, and PC-3) by MTT assay. Compound 2b showed significant growth inhibition against A549, AGS, HepG2, and HT-29 cancer cell lines with GI50 values in the range of 4.29-7.36 μM. Compound 44 was also found to be cytotoxic toward A549, AGS, HT-29 (most sensitive, GI50 = 1.54 μM), and PC-3 cancer cell lines. In the enzyme inhibition assay, compound 2b proved to be active as an HDAC inhibitor with an IC50 value of 11.5 μM. In addition, studies on compound 3 and 4 are still underway. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T06:16:04Z (GMT). No. of bitstreams: 1 ntu-96-R93423002-1.pdf: 1067601 bytes, checksum: 6d6c0edfd505e165784e0fb73b13edec (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 壹、緒論…………………………………………………1
1.1 Chromatin topology…………………………………………………4 1.2 HATs 與 HDACs…………………………………………………8 1.3 HDAC調控基因表現……………………………………………………10 1.4 HDAC與癌症…………………………………………………11 1.5 HDAC抑制劑(HDAC inhibitors,HDACi)…………………………………………………13 貳、目標化合物之設計…………………………………………………20 參、結果與討論…………………………………………………24 3.1 目標化合物之合成…………………………………………………24 3.1.1 目標化合物1之合成…………………………………………………24 3.1.2 目標化合物2之合成…………………………………………………34 3.1.3 目標化合物3,4之合成…………………………………………………38 3.2 生物活性測試…………………………………………………42 3.2.1 體外癌細胞毒性測試…………………………………………………42 3.2.2 HDAC酵素活性測試…………………………………………………44 肆、結論…………………………………………………46 伍、實驗部分…………………………………………………47 5.1 檢驗方法與實驗儀器…………………………………………………47 5.2 試藥以及溶劑…………………………………………………47 5.3 合成步驟…………………………………………………47 5.4 生物活性評估…………………………………………………64 陸、參考資料…………………………………………………68 | |
dc.language.iso | zh-TW | |
dc.title | Suberoylanilide Hydroxamic Acid (SAHA)類似物作為潛能抗癌藥物之設計與合成 | zh_TW |
dc.title | Design and Synthesis of Suberoylanilide Hydroxamic Acid (SAHA) Homologues as Potential Antitumor Agents | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王光昭,陳香惠,顧記華,忻凌偉 | |
dc.subject.keyword | 抗癌藥物,HDAC,抑制劑, | zh_TW |
dc.subject.keyword | SAHA,HDAC,anticancer, | en |
dc.relation.page | 75 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2007-01-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 1.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。